Dr. Giannios, holds a degree from the Medical School of Harvard University and John Hopkins University.  Dr. Giannios is certified by the American College of Surgeons. He has been selected for inclusion in the “Who is Who” in Medicine, and he has been elected by the International Biographical Centre in Cambridge as a top scientist in the arena of scientific research globally. He has been an opinion leader for the last two decades in genomic and epigenomic cancer medicine, where he has written four books and more than 5,000 lectures, posters, and publications in International Oncology Congresses and Journals with more than 500 awards in novel treatments based on personalized cancer medicine and translational medicine including oncology, cardiology, regenerative medicine, endocrinology, gynecology, neurology and other medical subspecialties where omic technology and nanomedicine might be applied mainly for tailoring individualized treatments to cancer patients with incurable solid tumors such as glioblastoma multiforme and metastatic tumors applying molecular targeting approaches for circumvention of chemo/radio/immune-resistant mechanisms using antisense treatments for downregulating antiapoptotic oncogenes and gene therapy or epigenetic therapy for re-expression of silenced apoptotic tumor suppressor genes. The induction of D2 irreversible stage of apoptosis is monitored by electron microscopy, where he has great expertise from the University of London.

Dr. Giannios, also holds several degrees, Dip lEngl from New York University, BSc(Biol)(USA), BSc(Chem)(USA), CertGCP(London), PGCertTMed(Edinburgh), PGDiplTMed(Edinburgh), MScTMed(Edinburgh), MD(AM) MPhil Med(London), PgCertFMed(Glasgow), cDSc (London), cLLB(Aberdeen), BCAM (USA), MD(AM)(Cal), FRSM(London), MRSC(Cambridge) and M/D Prof (London) in Translational Cancer Medicine. The four postgraduate degrees in Translational Medicine were earned with Distinction from the Medical School of the University of Edinburgh and London.